Search Videos and More
Dana-Farber Research Publication 12.1.2021
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.50 Years | Stem Cell Transplantation at Dana-Farber Brigham Cancer Center
New International Partnership to Accelerate Search for Cancer Cures
Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment
In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series
Antonio Giordano, MD, PhD; Sarah Sammons, MD; and Morgan Rutter, MS, BSN, RN, discuss advances in research and treatment for patients with triple negative metastatic breast cancer.Research Updates - Metastatic Breast Cancer
In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain
New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy
MatchMiner shortens time to identify appropriate precision medicine trials for individual patientsDana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine
Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.